Cision PR Newswire

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of...

U Power Limited Announces US$16 Million Private Placement Subscribed by Existing Shareholders

HONG KONG, Aug. 4, 2026 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) (the "Company" or "U Power"), a provider of AI-integrated solutions for next-generation...

Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced...

Boao Forum: CRRC Zhuzhou Institute Outlines Core Technologies and Application-Driven Innovation for Green Industry Growth

PERTH, Australia, Aug. 4, 2026 /PRNewswire/ -- At the Boao Forum for Asia Perth Conference on July 27, Li Donglin, Chairman of CRRC Zhuzhou...